United States — Food and Drug Administration & Nasdaq-100

United States — Food and Drug Administration: Reviva Pharmaceuticals Holdings is awaiting feedback from the United States — Food and Drug Administration regarding the use of a new form of brilaroxazine in its RECOVER-2 trial and future New Drug Application, which is crucial for extending patent protection.

Nasdaq-100: Reviva Pharmaceuticals Holdings' common stock will transition from Nasdaq-100 to the OTCQB Venture Market, which may affect its liquidity and volatility.

United States — Food and Drug Administration: The United States — Food and Drug Administration approved Eli Lilly and Company's weight loss pill, Foundayo, impacting the pharmaceutical market.

Nasdaq-100: The Nasdaq-100 exchange also experienced more advancing issues than decliners, contributing to the overall positive market performance.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of tabelecleucel's Biologics License Application due to manufacturing issues is a key factor in the lawsuit against Atara Biotherapeutics.

Nasdaq-100: Nasdaq-100 is the stock exchange where Atara Biotherapeutics' securities are traded.

United States — Food and Drug Administration: The United States — Food and Drug Administration approved Rolvedon, a key product in Assertio Holdings' portfolio, for the prevention of febrile neutropenia.

Nasdaq-100: Assertio Holdings will be delisted from Nasdaq-100 upon the completion of its acquisition by Astec LifeSciences.

Nasdaq-100: Nasdaq-100 is the stock exchange where Rhythm Pharmaceuticals, Inc. securities are traded.